Biointron’s Q4 2024 annual antibody report aims to explore the events and trends of the biopharmaceutical industry in 2024 (October, November, December). This quarter, 6 novel antibody drugs have been approved by at least one regulatory agency around the world: three monoclonal antibodies, two bispecific antibodies, and one antibody-drug conjugate (ADC).
1. Ongericimab (Junshida)
2. Marstacimab (Hympavzi)
3. Zanidatamab (Zilhera)
4. Sacituzumab tirumotecan (佳泰莱)
5. Zenocutuzumab (Bizengri)
6. Cosibelimab (Unloxcyt)
Q4 2024 saw several large collaborations and acquisitions of up to USD$1.9 billion in value. Investment in antibody drug startups focused on novel antibody platforms changing glycans, structure, and the use of artificial intelligence.
Gain exclusive insights into current trends such as:
• 📣 6 novel antibody drugs approved for the first time in Q4
• 💸 Top 10 antibody drug deals, including collaborations, M&As, and funding rounds of up to US$1.9B
• 📈 A focus on novel platforms from startups with millions in seed funding
• 🤖 Exciting uses for AI in antibody discovery
• 💊 A list of antibody drugs in regulatory review to keep an eye out for in Q1 2025
Biointron’s Q1 2025 annual antibody report aims to explore the events and trends of the biopharmaceutical industry in 2025 (January, February, March).
Resistance to treatment continues to limit the long-term success of many therapies. In oncology, cancers may evade antibody-based treatments through mechanisms such as antigen loss, impaired intracellular trafficking, or suppression of immune responses. To address these challenges, researchers are d
Antibody-drug conjugates (ADCs) couple the specificity of monoclonal antibodies with the cytotoxic potency of chemotherapeutic agents. Recent advances have been reported in both hematologic and solid tumors, with next-generation ADCs overcoming limitations of traditional therapies through improved t
Non–small cell lung cancer(NSCLC) remains the leading cause of cancer-related mortality worldwide. Since 2011, the U.S. Food and Drug Administration has approved over 30 new therapies for advanced NSCLC, primarily tyrosine kinase inhibitors and immune checkpoint inhibitors. Biologic age
ScientistとScience Exchangeとのご利用可能です。
